Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A disease model resource reveals core principles of tissue-specific cancer evolution.

Nature·2026
Same author

Exploring the Anticancer Properties and Mode of Action of Copper(II)-Furan Acylhydrazone on Human Triple Negative Breast Cancer Cells.

ChemMedChem·2026
Same author

Structural influences on the oxidation and anticancer activities of dicopper(II) complexes containing different selenium and sulfur ligands.

Dalton transactions (Cambridge, England : 2003)·2025
Same author

Combination of racotumomab immunotherapy with programmed death-1 blockade in a preclinical model of non-small cell lung cancer.

Translational lung cancer research·2025
Same author

Structural, spectroscopic, theoretical, and magnetic investigations of a novel cubane-like tetranuclear copper(II)-hydrazone complex.

Dalton transactions (Cambridge, England : 2003)·2025
Same author

Coated Bacterial Vaccine: A New Approach for Antigen Display on Bacterial Surface.

Biotechnology journal·2025

Related Experiment Video

Updated: Mar 29, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.4K

In Vitro and In Vivo Effects of a Copper(II)-Hydrazone Complex Against Human Osteosarcoma.

Lucía Santa Maria de la Parra1, Matías H Assandri2, Luisina M Solernó3,4

  • 1Centro de Química Inorgánica (CEQUINOR CCT-CONICET La Plata, Asociado a CIC), Departamento de Química, Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP), La Plata B1900, Buenos Aires, Argentina.

Pharmaceutics
|March 28, 2026
PubMed
Summary

A novel copper-hydrazone complex (Cu4L4) shows potent anticancer activity against osteosarcoma (OS) cells in vitro and in vivo. This new therapeutic agent effectively inhibits tumor growth and migration, offering a promising new avenue for OS treatment.

Keywords:
coppermetallodrugosteosarcomapreclinical studies

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.3K
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

12.0K

Related Experiment Videos

Last Updated: Mar 29, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.4K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.3K
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

12.0K

Area of Science:

  • Inorganic Chemistry
  • Medicinal Chemistry
  • Oncology

Background:

  • Osteosarcoma (OS) is a primary bone cancer in young individuals with poor outcomes.
  • Existing treatments for OS face challenges like relapse, metastasis, and chemoresistance.
  • Copper complexes are being explored as novel metal-based therapeutic agents.

Purpose of the Study:

  • To evaluate the in vitro and in vivo antitumor activity of a tetranuclear copper(II)-hydrazone complex (Cu4L4).
  • To investigate the mechanism of action of Cu4L4 against OS cells.
  • To compare the efficacy of Cu4L4 with its free ligand, cisplatin, and mononuclear analogs.

Main Methods:

  • Synthesized a tetranuclear Cu(II)-hydrazone complex (Cu4L4) from a thiophene-carbohydrazide derivative.
  • Performed in vitro cytotoxic assays on MG-63 OS cells and multicellular tumor spheroids.
  • Assessed clonogenic survival, reactive oxygen species (ROS) production, apoptosis, cell migration, and in vivo tumor growth in a xenograft model.

Main Results:

  • Cu4L4 exhibited potent cytotoxicity against OS cells (IC50 = 0.50 µM), significantly outperforming the free ligand and cisplatin.
  • The complex demonstrated enhanced antitumor activity compared to mononuclear copper-hydrazone analogs.
  • Cu4L4 induced ROS production and late apoptosis, inhibited cell migration, and reduced tumor growth by 43.6% in vivo with minimal toxicity.

Conclusions:

  • The tetranuclear copper-hydrazone complex (Cu4L4) displays significant and selective antitumor activity against osteosarcoma.
  • Cu4L4's mechanism involves ROS generation and apoptosis induction, making it a promising candidate for OS therapy.
  • Copper-hydrazone complexes represent a viable scaffold for developing novel osteosarcoma therapeutics.